In short
This article discusses the clinical trials of ARO-RAGE (ADS-015), an investigational inhalation solution being studied for the treatment of inflammatory lung disease, particularly asthma. The trials aim to assess the safety, tolerability, and effectiveness of ARO-RAGE in both healthy volunteers and patients with mild to moderate asthma. The study will evaluate different dosages and their effects on lung function and inflammation markers.
At a glance
- Drug Name
- ARO-RAGE (ADS-015)
- Drug Type
- Synthetic, double-stranded siRNA duplex conjugated to an αvβ6 integrin-targeting ligand
- Administration
- Inhalation solution using Pari eFlow Type 30XL nonvented vibrating mesh nebulizer system
- Target Condition
- Inflammatory Lung Disease, particularly asthma
- Study Phase
- Phase 1/2a
- Primary Objective
- Assess safety and tolerability in healthy volunteers and patients
- Secondary Objectives
- Evaluate lung function (FEV1, FVC, DLCO), pharmacokinetics, and pharmacodynamics
- Study Population
- Healthy volunteers and patients with mild to moderate asthma
- Dosing Schedule
- Two doses: Day 1 and Day 29
- Key Inclusion Criteria
- Physician-diagnosed asthma, stable medication regimen, specific lung function parameters
- Key Exclusion Criteria
- Recent respiratory infections, use of certain medications, significant comorbidities
What is ARO-RAGE (ADS-015)?
ARO-RAGE, also known as ADS-015, is a new investigational medication being developed for the treatment of inflammatory lung diseases. It is a synthetic, double-stranded siRNA (small interfering RNA) molecule that has been specially designed to target inflammation in the lungs.
How does it work?
ARO-RAGE works by targeting a specific protein called RAGE (Receptor for Advanced Glycation End-products). RAGE is involved in inflammatory processes in the lungs. By reducing the activity of RAGE, ARO-RAGE aims to decrease inflammation and potentially improve lung function in patients with inflammatory lung diseases.
What conditions does it treat?
ARO-RAGE is being investigated for the treatment of inflammatory lung diseases, with a specific focus on asthma. The current clinical trial is studying its effects in patients with mild to moderate asthma and those with high levels of airway inflammation.
How is it administered?
ARO-RAGE is administered as an inhalation solution using a special device called the Pari eFlow Type 30XL nonvented vibrating mesh nebulizer system. This device turns the medication into a fine mist that can be inhaled directly into the lungs.
Current research
ARO-RAGE is currently being studied in a Phase 1/2a clinical trial. This study aims to evaluate the safety, tolerability, and effectiveness of ARO-RAGE in healthy volunteers and patients with inflammatory lung disease, particularly asthma. The trial includes several groups (cohorts) of participants who will receive different doses of the medication or a placebo.
Who can participate in the study?
The study is looking for participants who meet specific criteria, including:
- Adults aged 18-65 years
- Diagnosed with asthma for at least 12 months
- Currently using asthma controller medications
- Non-smokers or former smokers who quit at least 6 months ago
There are also several exclusion criteria, such as recent respiratory infections, use of certain medications, or other medical conditions that might interfere with the study results.
Potential benefits
While the effectiveness of ARO-RAGE is still being studied, potential benefits for patients with inflammatory lung diseases could include:
- Reduced lung inflammation
- Improved lung function
- Better control of asthma symptoms
However, it's important to note that these potential benefits are still being investigated and have not been proven yet.
Safety considerations
As with any investigational medication, there may be risks and side effects associated with ARO-RAGE. The current study is designed to carefully monitor participants for any adverse effects. Some safety measures in the study include:
- Regular check-ups and lung function tests
- Monitoring of vital signs and laboratory tests
- Careful selection of participants to minimize risks
Participants in the study will be closely monitored by healthcare professionals throughout the trial period.